Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129496 | 0.87 | CHRM2 (0.40) | CHRM2CHRM1ALDH1A1KDM4EOPRD1 | |
| SCHEMBL5062392 | 0.86 | CHRM2 (0.40) | CHRM2CHRM1ALDH1A1KDM4EOPRD1 | |
| SCHEMBL3414469 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1ALDH1A1KDM4EOPRD1 | |
| SCHEMBL2586827 | 0.85 | — | — | |
| SCHEMBL28608744 | 0.85 | ALOX15 (0.43) | CHRM2CHRM1 | |
| SCHEMBL2490415 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1ALDH1A1KDM4EOPRD1 | |
| SCHEMBL4239133 | 0.84 | KMT2A (0.43) | CHRM2CHRM1ALDH1A1KDM4ELMNA | |
| SCHEMBL2411214 | 0.84 | KDM4E (0.34) | KDM4EKMT2APOLBHSD11B1 | |
| SCHEMBL3911963 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1ALDH1A1KDM4EOPRD1 | |
| SCHEMBL22345800 | 0.81 | CHRM2 (0.46) | CHRM2CHRM1ALDH1A1KDM4EOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077090-A1 | INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF | Miach Orthopaedics, Inc. (US) | 2026-03-19 | — | — | US | claimed |
| US-20260077091-A1 | INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF | Miach Orthopaedics, Inc. (US) | 2026-03-19 | — | — | US | claimed |
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | CELYNTRA THERAPEUTICS SA (BE) | 2025-12-25 | — | — | US | claimed |
| EP-3494396-B1 | CHEMILUMINESCENT AND FLUORESCENT SUBSTRATE PADS AND USES THEREOF | PIERCE BIOTECHNOLOGY INC (US) | 2025-06-11 | — | — | EP | claimed |
| CN-116057141-B | Ruthenium chemical mechanical polishing slurry containing titanium dioxide | CMC材料有限责任公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117860615-A | Covalent treatment of keratin-containing materials | 生活实验公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117777058-A | Synthesis method of 4- (2-hydroxyethyl) -1-piperazine propane sulfonic acid | 济宁亚科新材料科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117769570-A | Method for purifying immunoglobulin G and use thereof | 瑞士杰特贝林生物制品有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-112313727-B | Method and package for preparing buffer solution and kit for clinical test | 瑞乐文特生物有限公司 | 2023-12-22 | — | — | CN | claimed |
| US-20230384328-A1 | Creatinine Assay Kit with Desirable Stability and Capable of Rapidly Eliminating Drug Interference | Zhongshan BGH Biochem Co., Ltd. (CN) | 2023-11-30 | — | — | US | claimed |
| US-20030045003-A1 | Method for detection of the adulterant urine luckTM in urine using liquid chemistry, dry chemistry test pads, and lateral flow | SMITH JACK V (US) | 2003-03-06 | — | — | US | claimed |
| US-20030027350-A1 | Method for detection of bromine in urine using liquid chemistry, dry chemistry test pads, and lateral flow | SMITH JACK V (US) | 2003-02-06 | — | — | US | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | claimed |
| US-6451256-B1 | RECOMBINANT VIRUSES IN FROZEN OR LIQUID FORM, IN WHICH INFECTIOUS VIRUSES ARE PRESERVED IN AN AQUEOUS SOLUTION. THE RECOMBINANT VIRUS SUSPENSION COMPRISES AN AQUEOUS SUCROSE SOLUTION AT A CONCENTRATION FOR GENE THERAPY. | TRANSGENE S.A. (FR) | 2002-09-17 | — | — | US | claimed |
| US-6130040-A | FAST, SIMPLE, SPECIFIC BOND FORMATION BY CONTACTING FIRST STRAND OF NUCLEOTIDE SEQUENCES WITH SECOND STRAND WHICH HAS BEEN AMINO-BLOCKED AND MODIFIED BY CARBOXYLATION, PERMITTING HYBRIDIZATION AND BONDING | LIN SHI-LUNG (US) | 2000-10-10 | — | — | US | claimed |
| EP-0717645-B1 | REDUCTION OF SKIN IRRITATION AND RESISTANCE DURING ELECTROTRANSPORT | ALZA CORP (US) | 1998-05-13 | — | — | EP | claimed |
| US-5624415-A | MAINTAINING ANODIC RESERVOIR AT PH ABOVE 4 AND CATHODIC RESERVOIR AT PH BELOW 4 DURING ELECTROTRANSPORT AGENT DELIVERY | ALZA CORPORATION (US) | 1997-04-29 | — | — | US | claimed |
| EP-0717645-A1 | REDUCTION OF SKIN IRRITATION AND RESISTANCE DURING ELECTROTRANSPORT | ALZA CORPORATION (US) | 1996-06-26 | — | — | EP | claimed |
| WO-1995006497-A1 | REDUCTION OF SKIN IRRITATION AND RESISTANCE DURING ELECTROTRANSPORT | ALZA CORPORATION (US) | 1995-03-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077090-A1 | INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF | COL2A1, COL1A1, MMP13 | CHRM2 3849/4885CHRM1 4137/4885ALDH1A1 3864/4885 |
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | GDA, XPA, ERCC2 | CHRM2 4713/4885CHRM1 4726/4885ALDH1A1 4705/4885 |
| US-20260077091-A1 | INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF | COL2A1, COL1A1, COL14A1 | CHRM2 4426/4885CHRM1 4496/4885ALDH1A1 3160/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | CHRM2 23/4885CHRM1 46/4885ALDH1A1 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.